November 11, 2011 – Boston Scientific reported results from the EVOLVE first human use trial demonstrating the non ...
Stents
This channel includes news and new technology innovations for stents, also called vascular scaffolds. Stents are used to help prop open a vessel treated by balloon angioplasty because of the barotrauma caused by the extreme stretching of vessel walls. The stent enables to vessel to heal in an open position with collapsing. Drug eluting stents (DES) are coated in anti-proliferative drugs to precent scar tissue growth which can cause restenosis and occlude the vessel. DES require antiplatelet therapy because the drug carrier polymer on DES can cause thrombus inside the stent, even years after treatment, which is why bare metal stents are still used in some patients. This page includes news on coronary stents, carotid stents, peripheral stents, bioresorbable stents, and renal stents.
November 11, 2011 – Biosensors International Group announced two-year results from the BioFreedom first-in-human trial ...
November 11, 2011 — The 30-day results from the 8,500+ patient ADAPT-DES registry were presented at the 2011 TCT ...
While the current positive revolution in percutaneous coronary intervention (PCI) practice has been made possible by the ...
November 9, 2011 — Currently under review by the U.S. Food and Drug Administration (FDA), the Resolute drug-eluting ...
November 8, 2011 — Biosensors International Group Ltd. announced final results of the AXXESS PLUS trial, which ...
November 8, 2011 – Boston Scientific reports clinical endpoint data from its PLATINUM Long Lesion trial, demonstrating ...
November 7, 2011 – Abbott announced the company's schedule of key data presentations at the 23rd annual Transcatheter ...
November 7, 2011 – Arterial Remodeling Technologies (ART) reported that in vivo data strongly suggest that its second ...
November 4, 2011 — Medtronic Inc. announced approval by the U.S. Food and Drug Administration (FDA) of the Assurant ...
Nov. 2, 2011 – The U.S. Food and Drug Administration (FDA) granted market clearance for the Xience Prime everolimus ...
November 1, 2011 – Boston Scientific released the schedule of its major events and product-related clinical research for ...
October 25, 2011 — Stentys S.A. announced the publication of the results of the APPOSITION I clinical study in the ...
October 24, 2011 — BioCrossroads’ Indiana Seed Fund has announced its twelfth investment, committing $300,000 to medical ...
October 18, 2011 — Abbott announced the investigational Absorb bioresorbable vascular scaffold (BVS) has been recognized ...
October 18, 2011 — Boston Scientific Corp. has begun a phased launch of its Promus Element everolimus-eluting platinum ...